Global Transcatheter Heart Valve Market Set to Reach $15.14 Billion by 2030 with a Strong CAGR of 12.73% – ResearchAndMarkets.com

The global transcatheter heart valve market is estimated to witness substantial growth, reaching a projected value of US$ 15.14 Billion by 2030 at a robust compound annual growth rate (CAGR) of 12.73% from 2022 to 2030. Key Companies Mentioned: Over…

Read MoreGlobal Transcatheter Heart Valve Market Set to Reach $15.14 Billion by 2030 with a Strong CAGR of 12.73% – ResearchAndMarkets.com

Minimally Invasive Procedures and Growing Geriatric Population Fuel Global Aneurysm Clips Market Growth: Aesculap, Integra LifeSciences, and Galvani Bioelectronics Among Key Players

The global aneurysm clips market size is anticipated to reach USD 112.92 million by 2030, expanding at a CAGR of 7.36% from 2023 to 2030. The market is expected to grow due to the rising incidence of intracranial aneurysms, the…

Read MoreMinimally Invasive Procedures and Growing Geriatric Population Fuel Global Aneurysm Clips Market Growth: Aesculap, Integra LifeSciences, and Galvani Bioelectronics Among Key Players

Anticipated Surge in Global Gene Panel Market: Fuelled by Rising Prevalence of Genetic Disorders – ResearchAndMarkets.com

The Global Gene Panel Market to 2028 report has been added to ResearchAndMarkets.com’s offering. The global gene panel market is poised for impressive growth during the forecast period, driven by the increasing prevalence of genetic disorders such as Down syndrome, sickle cell disease, Tay-Sachs…

Read MoreAnticipated Surge in Global Gene Panel Market: Fuelled by Rising Prevalence of Genetic Disorders – ResearchAndMarkets.com

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive…

Read MoreNatera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

For the First Time Bioelectronic Medicine Researchers at The Feinstein Institutes Restore Feeling and Lasting Movement in Man Living With Quadriplegia

In a first-of-its-kind clinical trial, bioelectronic medicine researchers, engineers and surgeons at Northwell Health’s The Feinstein Institutes for Medical Research have successfully implanted microchips into the brain of a man living with paralysis, and have developed artificial intelligence (AI) algorithms to re-link his…

Read MoreFor the First Time Bioelectronic Medicine Researchers at The Feinstein Institutes Restore Feeling and Lasting Movement in Man Living With Quadriplegia

bspr Inc. and BHQ Corp. to Release First Smartphone App “Braincure” Beta Version Encompassing BHQ Actions for Brain Health, in the United States in September

bspr Inc. (Shibuya-ku, Tokyo, CEO: Yosuke Toyama), in collaboration with BHQ Corp. (Saitama City, Saitama Prefecture, CEO: Masahito Kawamori), is pleased to announce the release of the beta version of the smartphone app “Braincure” that utilizes the internationally standardized brain…

Read Morebspr Inc. and BHQ Corp. to Release First Smartphone App “Braincure” Beta Version Encompassing BHQ Actions for Brain Health, in the United States in September

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the staff of NYSE…

Read MoreNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive…

Read MoreNatera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer